Volume 153, Issue 4, Pages 890-892 (October 2017) Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct- Acting Antivirals: Case Closed?  Raoel Maan  Gastroenterology  Volume 153, Issue 4, Pages 890-892 (October 2017) DOI: 10.1053/j.gastro.2017.08.052 Copyright © 2017 AGA Institute Terms and Conditions

Figure 1 Sustained virological response is associated with a reduced risk of hepatocellular carcinoma. The adjusted hazard ratio for HCC in patients who achieve SVR compared to those who do not is lowest in those without cirrhosis, the largest number of patients in the HCV-infected population. A clear benefit is also seen in those with compensated cirrhosis, however data are still lacking on the benefit of SVR on HCC incidence in patients with decompensated cirrhosis and those with a prior history of HCC. Fortunately these groups comprise a small proportion of the HCV-infected population. Future studies will need to focus on these groups to clarify the risk of HCC after SVR. Gastroenterology 2017 153, 890-892DOI: (10.1053/j.gastro.2017.08.052) Copyright © 2017 AGA Institute Terms and Conditions